Cargando…

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

BACKGROUND: Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy. METHODS: We performed a retrospective study on severe COVID-19 patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campochiaro, Corrado, Della-Torre, Emanuel, Cavalli, Giulio, De Luca, Giacomo, Ripa, Marco, Boffini, Nicola, Tomelleri, Alessandro, Baldissera, Elena, Rovere-Querini, Patrizia, Ruggeri, Annalisa, Monti, Giacomo, De Cobelli, Francesco, Zangrillo, Alberto, Tresoldi, Moreno, Castagna, Antonella, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242960/ https://www.ncbi.nlm.nih.gov/pubmed/32482597 http://dx.doi.org/10.1016/j.ejim.2020.05.021

Ejemplares similares

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
por: De Luca, Giacomo, et al.
Publicado: (2020)

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
por: Cavalli, Giulio, et al.
Publicado: (2020)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

One year later: The case of tocilizumab in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Myocarditis: An Interleukin-1-Mediated Disease?
por: De Luca, Giacomo, et al.
Publicado: (2018)

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
por: Campochiaro, Corrado, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
por: Tomelleri, Alessandro, et al.
Publicado: (2020)

High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19
por: Ripa, Marco, et al.
Publicado: (2022)

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
por: Ripa, Marco, et al.
Publicado: (2021)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis
por: Ciceri, Fabio, et al.
Publicado: (2023)

Cardiovascular involvement in Erdheim–Chester diseases is associated with myocardial fibrosis and atrial dysfunction
por: Palmisano, Anna, et al.
Publicado: (2023)

Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave
por: Palumbo, Diego, et al.
Publicado: (2021)

Pulmonary Vascular Thrombosis in COVID-19 Pneumonia
por: De Cobelli, Francesco, et al.
Publicado: (2021)

Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement()
por: Natalello, Gerlando, et al.
Publicado: (2021)

Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19
por: Spagnuolo, V., et al.
Publicado: (2021)

Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19
por: Spagnuolo, V., et al.
Publicado: (2020)

A radiological predictor for pneumomediastinum/pneumothorax in COVID-19 ARDS patients
por: Palumbo, Diego, et al.
Publicado: (2021)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy
por: Ciceri, Fabio, et al.
Publicado: (2020)

Adult-onset Still’s disease complicated by Guillain-Barré syndrome
por: Farina, Nicola, et al.
Publicado: (2023)

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy
por: Zangrillo, Alberto, et al.
Publicado: (2023)

Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study
por: Conte, Caterina, et al.
Publicado: (2021)

Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis
por: Ramirez, Giuseppe A., et al.
Publicado: (2022)

505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2021)

Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2022)

Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?
por: Benedetti, Francesco, et al.
Publicado: (2020)

Correction to: Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?
por: Benedetti, Francesco, et al.
Publicado: (2021)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

P1638: CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) IS A RISK FACTOR FOR PULMONARY VASCULAR THROMBOSIS IN PATIENTS WITH COVID-19.
por: Aletti, Federico Mario, et al.
Publicado: (2023)

Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency
por: Zangrillo, Alberto, et al.
Publicado: (2023)

Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients
por: Mushtaq, Junaid, et al.
Publicado: (2020)

Recent exposure to smoking and COVID-19
por: Landoni, Giovanni, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jauqp4fii8s2a1um67r8u33vb8